146 related articles for article (PubMed ID: 18271519)
1. Novel sulfonanilide analogs decrease aromatase activity in breast cancer cells: synthesis, biological evaluation, and ligand-based pharmacophore identification.
Su B; Tian R; Darby MV; Brueggemeier RW
J Med Chem; 2008 Mar; 51(5):1126-35. PubMed ID: 18271519
[TBL] [Abstract][Full Text] [Related]
2. Selective regulation of aromatase expression for drug discovery.
Brueggemeier RW; Su B; Darby MV; Sugimoto Y
J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):207-10. PubMed ID: 19931613
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of selective aromatase expression regulators in breast cancer cells.
Su B; Landini S; Davis DD; Brueggemeier RW
J Med Chem; 2007 Apr; 50(7):1635-44. PubMed ID: 17315855
[TBL] [Abstract][Full Text] [Related]
4. Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition.
Su B; Diaz-Cruz ES; Landini S; Brueggemeier RW
J Med Chem; 2006 Feb; 49(4):1413-9. PubMed ID: 16480277
[TBL] [Abstract][Full Text] [Related]
5. Lead optimization of COX-2 inhibitor nimesulide analogs to overcome aromatase inhibitor resistance in breast cancer cells.
Su B; Chen S
Bioorg Med Chem Lett; 2009 Dec; 19(23):6733-5. PubMed ID: 19854050
[TBL] [Abstract][Full Text] [Related]
6. Aromatase and COX in breast cancer: enzyme inhibitors and beyond.
Brueggemeier RW; Su B; Sugimoto Y; Díaz-Cruz ES; Davis DD
J Steroid Biochem Mol Biol; 2007; 106(1-5):16-23. PubMed ID: 17616393
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of novel sulfonanilide compounds as antiproliferative agents for breast cancer.
Su B; Darby MV; Brueggemeier RW
J Comb Chem; 2008; 10(3):475-83. PubMed ID: 18380483
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, Aromatase Inhibitory, Antiproliferative and Molecular Modeling Studies of Functionally Diverse D-Ring Pregnenolone Pyrazoles.
Banday AH; Saeed BA; Al-Masoudi NA
Anticancer Agents Med Chem; 2021; 21(13):1671-1679. PubMed ID: 33238853
[TBL] [Abstract][Full Text] [Related]
9. Pyridine-substituted thiazolylphenol derivatives: Synthesis, modeling studies, aromatase inhibition, and antiproliferative activity evaluation.
Ertas M; Sahin Z; Berk B; Yurttas L; Biltekin SN; Demirayak S
Arch Pharm (Weinheim); 2018 Apr; 351(3-4):e1700272. PubMed ID: 29522642
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological characterization of 3-(imidazol-1-ylmethyl)piperidine sulfonamides as aromatase inhibitors.
Di Matteo M; Ammazzalorso A; Andreoli F; Caffa I; De Filippis B; Fantacuzzi M; Giampietro L; Maccallini C; Nencioni A; Parenti MD; Soncini D; Del Rio A; Amoroso R
Bioorg Med Chem Lett; 2016 Jul; 26(13):3192-3194. PubMed ID: 27161804
[TBL] [Abstract][Full Text] [Related]
11. Design and Pharmacophore Study of Triazole Analogues as Aromatase Inhibitors.
Banjare L
Anticancer Agents Med Chem; 2024; 24(4):288-303. PubMed ID: 37921212
[TBL] [Abstract][Full Text] [Related]
12. Recent developments in steroidal and nonsteroidal aromatase inhibitors for the chemoprevention of estrogen-dependent breast cancer.
Ahmad I; Shagufta
Eur J Med Chem; 2015 Sep; 102():375-86. PubMed ID: 26301554
[TBL] [Abstract][Full Text] [Related]
13. CoMFA, LeapFrog and blind docking studies on sulfonanilide derivatives acting as selective aromatase expression regulators.
Gueto C; Torres J; Vivas-Reyes R
Eur J Med Chem; 2009 Sep; 44(9):3445-51. PubMed ID: 19278756
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, biological evaluation, and docking study of indole aryl sulfonamides as aromatase inhibitors.
Fantacuzzi M; De Filippis B; Gallorini M; Ammazzalorso A; Giampietro L; Maccallini C; Aturki Z; Donati E; Ibrahim RS; Shawky E; Cataldi A; Amoroso R
Eur J Med Chem; 2020 Jan; 185():111815. PubMed ID: 31732252
[TBL] [Abstract][Full Text] [Related]
15. Analogue based drug design, synthesis, molecular docking and anticancer evaluation of novel chromene sulfonamide hybrids as aromatase inhibitors and apoptosis enhancers.
Ghorab MM; Alsaid MS; Al-Ansary GH; Abdel-Latif GA; Abou El Ella DA
Eur J Med Chem; 2016 Nov; 124():946-958. PubMed ID: 27770735
[TBL] [Abstract][Full Text] [Related]
16. COX-2 inhibitor nimesulide analogs are aromatase suppressors in breast cancer cells.
Su B; Cai X; Hong Y; Chen S
J Steroid Biochem Mol Biol; 2010 Oct; 122(4):232-8. PubMed ID: 20542113
[TBL] [Abstract][Full Text] [Related]
17. Pharmacophore modeling and in silico screening for new P450 19 (aromatase) inhibitors.
Schuster D; Laggner C; Steindl TM; Palusczak A; Hartmann RW; Langer T
J Chem Inf Model; 2006; 46(3):1301-11. PubMed ID: 16711749
[TBL] [Abstract][Full Text] [Related]
18. Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19).
Muftuoglu Y; Mustata G
Bioorg Med Chem Lett; 2010 May; 20(10):3050-64. PubMed ID: 20413308
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of carbon-11 labeled sulfonanilide analogues as new potential PET agents for imaging of aromatase in breast cancer.
Wang M; Lacy G; Gao M; Miller KD; Sledge GW; Zheng QH
Bioorg Med Chem Lett; 2007 Jan; 17(2):332-6. PubMed ID: 17095221
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of norendoxifen analogues with dual aromatase inhibitory and estrogen receptor modulatory activities.
Lv W; Liu J; Skaar TC; Flockhart DA; Cushman M
J Med Chem; 2015 Mar; 58(6):2623-48. PubMed ID: 25751283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
